Blockade of the CTLA-4 and PD1 immune checkpoints represents a potentially important anti-glioma strategy that has proven effective in preclinical models of glioma [30–34] and has warranted exploration in ongoing clinical trials [35]. This evidence concerns the gene PDCD1 and glioma.